Literature DB >> 29864903

Eicosapentaenoic acid improves endothelial function and nitric oxide bioavailability in a manner that is enhanced in combination with a statin.

R Preston Mason1, Hazem Dawoud2, Robert F Jacob3, Samuel C R Sherratt3, Tadeusz Malinski2.   

Abstract

The endothelium exerts many vasoprotective effects that are largely mediated by release of nitric oxide (NO). Endothelial dysfunction represents an early but reversible step in atherosclerosis and is characterized by a reduction in the bioavailability of NO. Previous studies have shown that eicosapentaenoic acid (EPA), an omega-3 fatty acid (O3FA), and statins individually improve endothelial cell function, but their effects in combination have not been tested. Through a series of in vitro experiments, this study evaluated the effects of a combined treatment of EPA and the active metabolite of atorvastatin (ATM) on endothelial cell function under conditions of oxidative stress. Specifically, the comparative and time-dependent effects of these agents on endothelial dysfunction were examined by measuring the levels of NO and peroxynitrite (ONOO-) released from human umbilical vein endothelial cells (HUVECs). The data suggest that combined treatment with EPA and ATM is beneficial to endothelial function and was unique to EPA and ATM since similar improvements could not be recapitulated by substituting another O3FA docosahexaenoic acid (DHA) or other TG-lowering agents such as fenofibrate, niacin, or gemfibrozil. Comparable beneficial effects were observed when HUVECs were pretreated with EPA and ATM before exposure to oxidative stress. Interestingly, the kinetics of EPA-based protection of endothelial function in response to oxidation were found to be significantly different than those of DHA. Lastly, the beneficial effects on endothelial function generated by combined treatment of EPA and ATM were reproduced when this study was expanded to an ex vivo model utilizing rat glomerular endothelial cells. Taken together, these findings suggest that a combined treatment of EPA and ATM can inhibit endothelial dysfunction that occurs in response to conditions such as hyperglycemia, oxidative stress, and dyslipidemia.
Copyright © 2018 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Entities:  

Keywords:  ATM; Atorvastatin; DHA; EPA; HUVEC; Oxidized small dense LDL; Small dense LDL

Mesh:

Substances:

Year:  2018        PMID: 29864903     DOI: 10.1016/j.biopha.2018.04.118

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  13 in total

Review 1.  Efficacy and Safety of Omega-3 Fatty Acids in the Prevention of Cardiovascular Disease: A Systematic Review and Meta-analysis.

Authors:  Jie Yan; Ming Liu; Danning Yang; Yu Zhang; Fengshuang An
Journal:  Cardiovasc Drugs Ther       Date:  2022-09-14       Impact factor: 3.947

Review 2.  Controversies in the Use of Omega-3 Fatty Acids to Prevent Atherosclerosis.

Authors:  Renato Quispe; Abdulhamied Alfaddagh; Brigitte Kazzi; Fawzi Zghyer; Francoise A Marvel; Roger S Blumenthal; Garima Sharma; Seth S Martin
Journal:  Curr Atheroscler Rep       Date:  2022-04-30       Impact factor: 5.967

Review 3.  A Fishy Topic: VITAL, REDUCE-IT, STRENGTH, and Beyond: Putting Omega-3 Fatty Acids into Practice in 2021.

Authors:  Tahreem Iqbal; Michael Miller
Journal:  Curr Cardiol Rep       Date:  2021-07-11       Impact factor: 2.931

Review 4.  New Insights into Mechanisms of Action for Omega-3 Fatty Acids in Atherothrombotic Cardiovascular Disease.

Authors:  R Preston Mason
Journal:  Curr Atheroscler Rep       Date:  2019-01-12       Impact factor: 5.113

Review 5.  Advances in the Study of Marine Products with Lipid-Lowering Properties.

Authors:  Jiarui Zhao; Qi Cao; Maochen Xing; Han Xiao; Zeyu Cheng; Shuliang Song; Aiguo Ji
Journal:  Mar Drugs       Date:  2020-07-27       Impact factor: 5.118

6.  Mechanistic insights into cardiovascular protection for omega-3 fatty acids and their bioactive lipid metabolites.

Authors:  Timothy D O'Connell; Richard Preston Mason; Matthew J Budoff; Ann Marie Navar; Gregory C Shearer
Journal:  Eur Heart J Suppl       Date:  2020-10-06       Impact factor: 1.803

7.  Secular Decreasing Trend in Plasma Eicosapentaenoic and Docosahexaenoic Acids among Patients with Acute Coronary Syndrome from 2011 to 2019: A Single Center Descriptive Study.

Authors:  Tomoaki Okada; Toru Miyoshi; Masayuki Doi; Kosuke Seiyama; Wataru Takagi; Masahiro Sogo; Kazumasa Nosaka; Masahiko Takahashi; Keisuke Okawa; Hiroshi Ito
Journal:  Nutrients       Date:  2021-01-17       Impact factor: 5.717

8.  Emerging Mechanisms of Cardiovascular Protection for the Omega-3 Fatty Acid Eicosapentaenoic Acid.

Authors:  R Preston Mason; Peter Libby; Deepak L Bhatt
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-03-26       Impact factor: 8.311

9.  Anti-Inflammatory and Anti-Apoptotic Effects of Stybenpropol A on Human Umbilical Vein Endothelial Cells.

Authors:  Li Zhang; Feifei Wang; Qing Zhang; Qiuming Liang; Shumei Wang; Minghua Xian; Feng Wang
Journal:  Int J Mol Sci       Date:  2019-10-29       Impact factor: 5.923

Review 10.  The Road to Approval: a Perspective on the Role of Icosapent Ethyl in Cardiovascular Risk Reduction.

Authors:  Xiaowen Wang; Subodh Verma; R Preston Mason; Deepak L Bhatt
Journal:  Curr Diab Rep       Date:  2020-10-23       Impact factor: 4.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.